These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6177009)

  • 41. Free and total PSA in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
    Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue.
    Lein M; Nowak L; Jung K; Laube C; Ulbricht N; Schnorr D; Loening SA
    Ann N Y Acad Sci; 1999 Jun; 878():544-6. PubMed ID: 10415768
    [No Abstract]   [Full Text] [Related]  

  • 44. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
    Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
    Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
    Stephan C; Jung K; Diamandis EP; Rittenhouse HG; Lein M; Loening SA
    Urology; 2002 Jan; 59(1):2-8. PubMed ID: 11796270
    [No Abstract]   [Full Text] [Related]  

  • 46. Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor.
    Ritter JM
    Br J Pharmacol; 1984 Oct; 83(2):409-18. PubMed ID: 6386089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening SA
    J Urol; 1999 Aug; 162(2):502-3. PubMed ID: 10411077
    [No Abstract]   [Full Text] [Related]  

  • 48. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
    Yesner R; Kelly LJ; Chan YK
    Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of eicosapentaenoic acid (EPA) on prostacyclin production in diabetics: GC/MS analysis of PGI2 and PGI3 levels.
    Nishikawa M; Hishinuma T; Nagata K; Koseki Y; Suzuki K; Mizugaki M
    Methods Find Exp Clin Pharmacol; 1997; 19(6):429-33. PubMed ID: 9385592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simultaneous determination of prostanoids in plasma by gas chromatography-negative-ion chemical-ionization mass spectrometry.
    Schweer H; Kammer J; Seyberth HW
    J Chromatogr; 1985 Mar; 338(2):273-80. PubMed ID: 3858280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of the quantitative analysis of 6-oxo-PGF1 alpha in biological fluids by gas chromatography mass spectrometry and radioimmunoassay.
    Hensby CN; Jogee M; Elder MG; Myatt L
    Biomed Mass Spectrom; 1981 Mar; 8(3):111-7. PubMed ID: 6894556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of a single episode of exertion on serum 6-keto-PGF1 alpha concentration in healthy individuals and patients with exercise-induced stable angina pectoris].
    Halawa B; Mazurek W
    Pol Tyg Lek; 1989 Jun; 44(23):554-6. PubMed ID: 2631072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological half-life of prostacyclin and 6-oxo-PGF1 alpha levels in plasma of patients with colonic cancer.
    Polterauer P; Sinzinger H; Peskar BA
    Prostaglandins Leukot Med; 1986 Jun; 22(3):249-58. PubMed ID: 3523543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative analysis of 6-keto-prostaglandin F1 alpha in biological fluids.
    Morita I; Murota S; Miyatake T; Ohno T; Suzuki M
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():95-7. PubMed ID: 2936209
    [No Abstract]   [Full Text] [Related]  

  • 55. Factors affecting the production of prostacyclin in man.
    Hensby CN; Webster J; Lewis PJ; Crowley KT; Dollery CT
    Prog Lipid Res; 1981; 20():565-7. PubMed ID: 7043484
    [No Abstract]   [Full Text] [Related]  

  • 56. Solid- and liquid-phase extraction for the gas chromatographic-tandem mass spectrometric quantification of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-oxo-prostaglandin F1 alpha in human urine.
    Tsikas D; Gutzki FM; Böhme M; Fuchs I; Frölich JC
    J Chromatogr A; 2000 Jul; 885(1-2):351-9. PubMed ID: 10941682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
    Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
    Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Release of prostacyclin in vivo and its role in man.
    Ritter JM; Barrow SE; Blair IA; Dollery CT
    Lancet; 1983 Feb; 1(8320):317-9. PubMed ID: 6130331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 6-oxo-PGF1 alpha -a new tumour marker for tumours in the maxillo-facial region.
    Matejka M; Gisinger C; Porteder H; Watzek G; Sinzinger H
    J Maxillofac Surg; 1983 Aug; 11(4):157-9. PubMed ID: 6579146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determination of peripheral plasma prostanoid concentration: an unreliable index of 'in vivo' prostanoid activity.
    Schweer H; Kammer J; Kühl PG; Seyberth HW
    Eur J Clin Pharmacol; 1986; 31(3):303-5. PubMed ID: 3466793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.